Every reference with a DOI in the deposited reference list resolved to a known
work in Crossref or DataCite at the dated check, and none carried a retraction,
withdrawal, or removal notice.
The 25 checked references that resolve
resolves10.2139/ssrn.1443412Did TRIPS Spur Innovation? An Empirical Analysis of Patent Duration and Incentives to Innovate
resolves10.1257/aer.20131176Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
resolves10.1257/aer.20141301The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India
resolves10.1093/qje/qju029Patents and Cumulative Innovation: Causal Evidence from the Courts
*
resolves10.1086/662721Waiting to Imitate: On the Dynamic Pricing of Knowledge
resolves10.1257/aer.99.2.343The Empirical Impact of Intellectual Property Rights on Innovation: Puzzles and Clues
resolves10.2307/2696399Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patent Law Reforms
resolves10.3386/w21666How Do Patents Affect Follow-On Innovation? Evidence from the Human Genome
The 26 references without a DOI — listed, not checked
no DOI — not checkedref7
no DOI — not checkedref9
no DOI — not checkedref10
no DOI — not checkedref13
no DOI — not checkedCompetition between generic and branded drugs
no DOI — not checkedThe distribution of sales revenues from pharmaceutical innovation
no DOI — not checkedWhen do generics challenge drug patents?
no DOI — not checkedEarning Exclusivity: Generic Drug Incentives and the Hatch-Waxman Act
no DOI — not checkedref23
no DOI — not checkedref26
no DOI — not checkedCharacteristics of patent litigation: A window on competition
no DOI — not checkedLanjouw and Mark Schankerman Patent Quality and Research Productivity: Measuring Innovation with Multiple Indicators
no DOI — not checkedExaminer characteristics and patent oce outcomes
no DOI — not checkedref35
no DOI — not checkedThe optimum life of a patent: Reply
no DOI — not checkedref37
no DOI — not checkedref38
no DOI — not checkedref41
no DOI — not checkedref42
no DOI — not checkedThe US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry -180-day exclusivity when multiple ANDAs are submitted on the same day
no DOI — not checkedFood and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry -Listed drugs, 30-month stays, and approval of ANDAs and 505(b)(2) applications under HatchWaxman, as amended by the Medicare Prescription Drug, Improvement, and Modernization Act of
no DOI — not checkedOn the optimal patent policy
no DOI — not checkedRevitalizing the patent system to incentives pharmaceutical innovation: the potential claims with means-plus-function clauses
no DOI — not checkedThe economics of product patents
no DOI — not checkedGeneric competition and pharmaceutical innovation: The Drug Price Competition and Patent Term Restoration Act of 1984
no DOI — not checkedref51
checked 2026-08-27 — re-checked daily as this page is visited;
titles and statuses come from Crossref and DataCite and are not part of the signed record
Both snippets point at the live badge image and link back to this page. The
badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.